In other words, it is not a synthetic invention so much as a naturally occurring signaling molecule that researchers have tried to understand and, in places, to study therapeutically
The resolution of this paradox likely involves dose, individual neurological vulnerability, and the difference between GLP-1 receptor activation in different nervous system compartments
Whether it lives up to its Phase 2 and Phase 3 promise across the full TRIUMPH program will determine whether it becomes the new standard of care or remains one option among several
75, S67S81
Fernandez-Mendivil C, Luengo E, Trigo-Alonso P, Garcia-Magro N, Negredo P, Lopez MG
Knockout clones were identified by western blotting